Literature DB >> 814104

Fc- and complement-receptor rosette-forming cell ratios in human tonsils and peripheral blood.

I Siegel, M H Grieco, S Gupta.   

Abstract

Lymphocytes were investigated for both Fc- and complement-rosette-forming cell activities. At least three subpopulations differing in the relative activities of the Fc and complement receptors have been disclosed. In human tonsils a subpopulation of B lymphocytes had a higher complement-receptor activity than Fc-receptor activity. In contrast, the peripheral cells from a patient with a lymphoma and another with an undiagnosed lymphocytic disease contained a population of B lymphocytes with higher Fc-receptor than complement- receptor activity. In three patients with chronic lymphocytic leukemia, B lymphocytes contained both Fc- and complement-receptor activities. No differences between complement- and Fc-receptor activities were evident in normal human peripheral blood. Fc-receptor, but not complement-receptor activity was inhibited by 2% gamma-globulin, or 8 X 10(3) M iodoacetate. EDTA at 1.7 X 19(-2) M concentration has no effect upon Fc- or complement-rosette-forming cells. The activity of both receptors was diminished at 4 degrees C.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 814104     DOI: 10.1159/000231538

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  3 in total

1.  Study of human T and B lymphocytes with heterologous antisera. IV. Subpopulations in tonsil and adenoid cell suspensions.

Authors:  J Brochier; C Samarut; L T Bich-Thuy; J P Revillard
Journal:  Immunology       Date:  1978-11       Impact factor: 7.397

2.  Clinical immunological study of T lymphocytes and EA rosette forming cells in tonsils.

Authors:  L Gyeney; K Merétey; A Falus; U Böhm; S Bozsóky
Journal:  Arch Otorhinolaryngol       Date:  1978-09-28

3.  Rosette formation with mouse erythrocytes. III. Studies in patients with primary immunodeficiency and lymphoproliferative disorders.

Authors:  S Gupta; R A Good; F P Siegal
Journal:  Clin Exp Immunol       Date:  1976-11       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.